"The U.S. Food and Drug Administration today approved Dotarem (gadoterate meglumine) for use in magnetic resonance imaging (MRI) of the brain, spine and associated tissues of patients ages 2 years and older.
Dotarem is a gadolinium-based"...
- Patient Information:
Details with Side Effects
Overdoses with doses up to 70 mg per kg have been reported in clinical studies and post-marketing experience with Synagis, and in some cases, adverse reactions were reported. In case of overdosage, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment instituted.
Synagis is contraindicated in children who have had a previous significant hypersensitivity reaction to Synagis [see WARNINGS AND PRECAUTIONS].
Last reviewed on RxList: 4/17/2012
This monograph has been modified to include the generic and brand name in many instances.
Additional Synagis Information
Synagis - User Reviews
Synagis User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.